AstraZeneca–Bristol Myers Squibb Merger Talks: Is the $400 Billion Pharma Deal Confirmed?

AstraZeneca and Bristol Myers Squibb are reportedly exploring a combination that could create a pharmaceutical group worth close to $400 billion. The possibility has immediate implications for AZN and BMY shareholders, but it remains a reported discussion—not a confirmed merger.

The companies have held talks during recent months, according to the Financial Times report. Neither business has disclosed an offer, ownership arrangement, financing plan or timetable, and the discussions could still be delayed or abandoned.

The first number to understand is $400 billion

The headline figure does not mean AstraZeneca has offered $400 billion to buy Bristol Myers Squibb. It is based on the companies’ approximate combined market values when the report emerged.

AstraZeneca was valued at around $264 billion, while Bristol Myers Squibb was worth approximately $133 billion. Any formal transaction could carry a different value after including a takeover premium, debt, cash and newly issued shares.

Before the report, AstraZeneca’s New York-listed shares closed at $169.64, more than $40 below their 52-week high. Bristol Myers Squibb ended at $65.31, close to its 52-week high of $65.66 after gaining approximately 48% over the previous year.

The deal logic begins with cancer medicines

AstraZeneca generated approximately $25.6 billion from oncology medicines in 2025, nearly half of its $58.7 billion total revenue. Its major treatments include Tagrisso, Imfinzi, Lynparza and Enhertu.

Bristol Myers Squibb would contribute a substantial portfolio led by Opdivo and Yervoy, together with Reblozyl and the cell therapy Breyanzi. Its wider business includes Eliquis for cardiovascular conditions, Camzyos, Sotyktu and the neuroscience medicine Cobenfy.

AstraZeneca has repeatedly used deals and partnerships to expand its research pipeline. Earlier AstraZeneca takeover speculation involving Abivax showed how acquisition rumours can quickly affect AZN shares, even before an agreement exists.

Bristol Myers Squibb brings growth and patent risk

Bristol Myers Squibb reported second-quarter revenue of $12.97 billion and adjusted earnings of $2.04 per share, both above market expectations. Revenue from its newer growth products reached $7.56 billion, an increase of 15%, helping the company raise its full-year forecast.

The pressure comes from established medicines facing patent expirations, generic competition or biosimilar rivals. When a blockbuster medicine loses exclusivity, its revenue can decline quickly as cheaper alternatives reach the market.

That pressure is driving consolidation across the industry. The same search for future growth was visible when Gilead agreed to acquire Arcellx for $7.8 billion, although an AstraZeneca–BMS combination would operate on a dramatically larger scale.

AstraZeneca is already shifting closer to America

AstraZeneca reported second-quarter revenue of $15.38 billion and core earnings of $2.63 per share. It continues to target $80 billion in annual revenue by 2030 and expects more than 20 major clinical or regulatory data readouts over the next 18 months.

The company has committed $50 billion to US manufacturing and research. It has also strengthened its New York listing while retaining its London listing and Cambridge headquarters.

A merger with New Jersey-based Bristol Myers Squibb would deepen AstraZeneca’s US presence. It would also renew concerns in Britain about where the combined company would be headquartered and how UK research facilities and jobs would be treated.

What shareholders do not know yet

BMY investors do not know whether they would receive cash, AstraZeneca shares or both. They also cannot calculate a potential takeover premium because no price or exchange ratio has been disclosed.

AZN investors would need to examine the cost of financing the transaction, possible share dilution and whether expected savings justified the risks of integrating two global businesses.

No leadership arrangement has been reported. It is also unclear whether the transaction would be structured as an AstraZeneca acquisition, a merger of equals or another form of combination.

Cancer-drug overlap creates a regulatory test

A deal would likely require reviews by the US Federal Trade Commission, Britain’s Competition and Markets Authority and the European Commission.

Regulators would examine competition between AstraZeneca’s Imfinzi and Bristol Myers Squibb’s Opdivo, along with overlapping clinical trials and future oncology treatments. Authorities could require product sales, transferred licences or the separation of research programmes.

For patients, a larger research platform could bring more funding, clinical-trial capacity and manufacturing scale. The counterargument is that fewer independent competitors could affect medicine prices and reduce competition in important treatment areas.

The UK remembers Pfizer’s failed approach

AstraZeneca employs around 10,000 people across five UK locations, including major operations in Cambridge and Macclesfield. Questions about employment and research commitments recall Pfizer’s unsuccessful approach in 2014, which AstraZeneca rejected amid political and scientific concerns.

Bristol Myers Squibb is scheduled to report third-quarter results on October 29, followed by AstraZeneca on October 30. A formal company statement or regulatory filing before then would be the clearest indication that the reported talks have advanced.

Until that happens, the $400 billion combination should be treated as a possible merger under discussion—not an agreed or completed deal.